Literature DB >> 22989730

Persistent neck disease after chemoradiation for head and neck squamous cell carcinoma.

J G Sanders1, K G Smith, M B Jameson, C de Groot, J White.   

Abstract

OBJECTIVE: This study aimed to identify the incidence of residual viable neck disease in patients with mucosal squamous cell carcinoma of the upper aero-digestive tract, following primary chemoradiation at a tertiary centre. STUDY
DESIGN: Retrospective review.
METHODS: Retrospective chart review of patients treated with primary chemoradiation for squamous cell carcinoma of the aero-digestive tract between August 2001 and August 2008. Neck status pre- and post-treatment was the primary focus.
RESULTS: Forty-two patients with node-positive disease prior to chemoradiation were included. Thirty-seven (88.1 per cent) achieved complete response to treatment: no patient in this group underwent neck dissection, five died due to recurrence at the primary site or distant metastasis, and none suffered neck recurrence. Five (11.9 per cent) patients achieved partial response to chemoradiation and underwent neck dissection; viable tumour was found in one patient.
CONCLUSION: Our data support conservative management of the neck in patients with complete response to chemoradiation, and consolidation neck dissection in patients with partial response.

Entities:  

Mesh:

Year:  2012        PMID: 22989730     DOI: 10.1017/S0022215112002009

Source DB:  PubMed          Journal:  J Laryngol Otol        ISSN: 0022-2151            Impact factor:   1.469


  2 in total

1.  Outcomes after primary intensity-modulated radiation therapy for oropharyngeal squamous cell carcinoma at a New Zealand regional cancer centre: Impact of p16 status.

Authors:  Saad Maqsood; Michael B Jameson; Charles De Groot; Cristian Hartopeanu; Nur Azri Bin Haji Mohd Yasin; Ziad Thotathil
Journal:  Cancer Rep (Hoboken)       Date:  2018-04-10

2.  Metastasis of nasopharyngeal carcinoma to parotid lymph nodes: a retrospective study.

Authors:  Shengye Wang; Jianlin Lou; Suzhan Zhang; Liang Guo; Kejing Wang; Minghua Ge
Journal:  World J Surg Oncol       Date:  2015-01-26       Impact factor: 2.754

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.